Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBCBS Iowa Vyjuvek Coverage Policy | OpenPayer
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield - IowaPolicy 05.05.11

    Vyjuvek (beremagene geperpavec-svdt) Coverage Criteria

    Customize your policy alerts

    Sign up for Blue Cross Blue Shield - Iowa Policy 05.05.11 alerts

    Get alerted when Policy 05.05.11 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Prior authorization coverage for Vyjuvek to treat wounds in adult and pediatric members with dystrophic epidermolysis bullosa and COL7A1 mutations, including clinical eligibility, documentation, dosing, continuation, and billing requirements.

    Policy Summary
    PayerBlue Cross Blue Shield - Iowa
    PolicyVyjuvek (beremagene geperpavec-svdt)
    Policy CodePolicy 05.05.11
    Change TypeNo material clinical or coverage change
    Effective DateOct 3, 2026
    Last ReviewAug 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization requests with clinical and genetic documentation initially and evidence of positive clinical response for continuation.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    6 monthsInitial and continuation authorization period
    COL7A1Genetic confirmation required
    4 cartons/28 daysStandard quantity limit
    No active infectionTarget wound eligibility

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Not allowed
    Same-wound combination therapy

    Coverage Criteria

    Initial Therapy

    Authorization of 6 months may be granted for treatment of wounds in members with dystrophic epidermolysis bullosa when all of the following criteria are met:

    Initial therapy eligibility

    • Disease and treatment eligibility

      • Diagnosis: Member has a diagnosis of dystrophic epidermolysis bullosa (DEB).
      • Clinical manifestations: Member has clinical manifestations of disease, such as extensive skin blistering, skin erosions, or scarring.
      • Genetic confirmation: Member has genetic test results confirming a mutation in the COL7A1 gene.
      • Target wound: Member has one or more open wounds that will be treated (target wounds).

        Target wounds are the wounds selected for treatment.

    • Target wound requirements

      • Wound quality: Target wound has adequate granulation tissue and vascularization.
      • Cancer exclusion: Member does not have a history of squamous cell carcinoma in the affected wound(s) that will receive treatment.
      • Infection exclusion: Member does not have an active infection in the affected wound(s) that will receive treatment.
    • Recent graft exclusion: Member has not received a skin graft in the past three months.
    • Combination therapy exclusion: Vyjuvek will not be used in combination with Filsuvez (birch triterpenes) or Zevaskyn (prademagene zamikeracel) in the same wound.

    Continuation Therapy

    Authorization of 6 months may be granted for treatment of wounds in members with dystrophic epidermolysis bullosa when all of the following criteria are met:

    Continuation therapy eligibility

    • Clinical response: Member achieves or maintains a positive clinical response to Vyjuvek therapy, such as a decrease in wound size, increase in granulation tissue, or complete wound closure.
    • Cancer exclusion: Member does not have current evidence or a history of squamous cell carcinoma in the affected wound(s) that will receive treatment.
    • Recent graft exclusion: Member has not received a skin graft in the past three months.
    • Infection exclusion: Member does not have an active infection in the affected wound(s) that will receive treatment.

    Vyjuvek must not be used in combination with Filsuvez (birch triterpenes) or Zevaskyn (prademagene zamikeracel) in the same wound.

    The affected target wound must not have an active infection. The member must not have the applicable squamous cell carcinoma exclusion: no history of squamous cell carcinoma in the affected wound for initial approval, and no current evidence or history of squamous cell carcinoma in the affected wound for continuation therapy.

    The member must not have received a skin graft within the past three months for Vyjuvek authorization.

    Vyjuvek is considered not medically necessary for continuation when the member does not meet the continuation criteria, including failure to achieve or maintain a positive clinical response or failure to meet the required wound characteristics and safety exclusions.

    Coding and Administration

    HCPCS CodeHCPCS
    J3401Beremagene geperpavec-svdt for topical administration, containing nominal 5 x 10^9 pfu/ml vector genomes, per 0.1 ml
    Standard Quantity Limit
    MedicationVyjuvek 5 × 10^9 PFU carton
    Standard quantity limit4 cartons
    Limit periodPer 28 days
    FDA-Recommended Administration
    MedicationVyjuvek
    AdministrationApply to selected wound(s)
    FrequencyOnce a week

    Provider Requirements and Coverage Risks

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for Vyjuvek. Initial authorization may be granted for 6 months when the initial clinical criteria are met; continuation authorization may be granted for an additional 6 months when continuation criteria are met.

    • Submit the required documentation with both initial and continuation requests.
    • Coverage is subject to the member having no applicable exclusions.
    Documentation Required

    Initial Request Documentation

    For an initial request, submit medical records documenting the clinical manifestations of dystrophic epidermolysis bullosa and genetic test results confirming a mutation in the COL7A1 gene.

    • Medical records must document clinical manifestations such as extensive skin blistering, skin erosions, or scarring.

    Therapy Background

    Vyjuvek (beremagene geperpavec-svdt) is an HSV-1 vector-based gene therapy indicated for treating wounds in adult and pediatric patients with dystrophic epidermolysis bullosa caused by mutation(s) in the COL7A1 gene.

    Initial Therapy Criteria

    Initial Therapy

    Authorization of 6 months may be granted for treatment of wounds in members with dystrophic epidermolysis bullosa when all of the following criteria are met:

    Initial therapy eligibility

    • Disease and treatment eligibility

      • Diagnosis: Member has a diagnosis of dystrophic epidermolysis bullosa (DEB).
      • Clinical manifestations: Member has clinical manifestations of disease, such as extensive skin blistering, skin erosions, or scarring.
      • Genetic confirmation: Member has genetic test results confirming a mutation in the COL7A1 gene.

    Continuation Therapy Criteria

    Continuation Therapy

    Authorization of 6 months may be granted for treatment of wounds in members with dystrophic epidermolysis bullosa when all of the following criteria are met:

    Continuation therapy eligibility

    • Clinical response: Member achieves or maintains a positive clinical response to Vyjuvek therapy, such as a decrease in wound size, increase in granulation tissue, or complete wound closure.
    • Cancer exclusion: Member does not have current evidence or a history of squamous cell carcinoma in the affected wound(s) that will receive treatment.
    • Recent graft exclusion: Member has not received a skin graft in the past three months.

    Quantity and Dose Limits

    Vyjuvek Quantity Limit
    MedicationVyjuvek 5 × 10^9 PFU carton
    Quantity limit4 cartons
    Limit periodPer 28 days
    Vyjuvek Administration
    MedicationVyjuvek
    ApplicationApply to selected wound(s)
    FrequencyOnce a week
    Policy Summary
    PayerBlue Cross Blue Shield - Iowa
    PolicyVyjuvek (beremagene geperpavec-svdt)
    Policy CodePolicy 05.05.11
    Change TypeNo material clinical or coverage change
    Effective DateOct 3, 2026
    Last ReviewAug 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization requests with clinical and genetic documentation initially and evidence of positive clinical response for continuation.
    SourceLink
    On This Page
    Coverage CriteriaCoding and AdministrationProvider Requirements and Coverage RisksTherapy BackgroundInitial Therapy CriteriaContinuation Therapy CriteriaQuantity and Dose Limits
  1. Target wound quality: Member's target wound has adequate granulation tissue and vascularization.
  2. Combination therapy exclusion: Vyjuvek will not be used in combination with Filsuvez (birch triterpenes) or Zevaskyn (prademagene zamikeracel) in the same wound.
  3. Maximum Weekly Dose
    Age rangeMembers older than 3 years
    Maximum weekly dose4 × 10^9 PFU
    Maximum weekly volume2 mL
  4. Genetic testing must confirm a COL7A1 mutation.
  5. Documentation Required

    Continuation Request Documentation

    For a continuation request, submit chart notes or medical record documentation supporting a positive clinical response to Vyjuvek therapy.

    • Documentation may support a decrease in wound size, increased granulation tissue, or complete wound closure.
    Note

    Qualified Prescriber or Consultant

    Vyjuvek must be prescribed by, or used in consultation with, a dermatologist or wound care specialist with expertise in treating dystrophic epidermolysis bullosa (DEB).

    • The qualified prescriber or consultant must have relevant DEB treatment expertise.
    Denial Risk

    Initial Eligibility Documentation

    An initial authorization request is at risk of denial when the required diagnosis, genetic confirmation, or target wound is not documented.

    • The member must have a diagnosis of dystrophic epidermolysis bullosa (DEB).
    • Clinical manifestations of DEB must be documented.
    • Genetic test results must confirm a COL7A1 mutation.
    • The member must have one or more open wounds identified for treatment as target wounds.
    Denial Risk

    Disqualifying Wound Characteristics

    Authorization may be denied when a target wound lacks adequate granulation tissue or vascularization, has an active infection, or has other disqualifying characteristics.

    • The affected wound must have adequate granulation tissue and vascularization.
    • The affected wound must not have an active infection.
    • The member must not have current evidence or a history of squamous cell carcinoma in the affected wound(s).
    Denial Risk

    Recent Graft or Prohibited Combination

    Authorization may be denied if the member received a skin graft within the past three months or if Vyjuvek will be used with another prohibited therapy in the same wound.

    • No skin graft may have been received in the past three months.
    • Do not use Vyjuvek in combination with Filsuvez (birch triterpenes) or Zevaskyn (prademagene zamikeracel) in the same wound.
    Denial Risk

    Insufficient Response for Continuation

    Continuation authorization may be denied when the member does not achieve or maintain a positive clinical response to Vyjuvek or otherwise fails to meet the continuation criteria.

    • Document a positive response, such as decreased wound size, increased granulation tissue, or complete wound closure.
    • Continuation criteria also require an eligible target wound, no applicable squamous cell carcinoma, no recent skin graft, no active infection, adequate granulation tissue and vascularization, and no prohibited same-wound combination therapy.
    • Vyjuvek is not medically necessary when the applicable criteria are not met.
    Target wound: Member has one or more open wounds that will be treated (target wounds).

    Target wounds are the wounds selected for treatment.

  6. Target wound requirements

    • Wound quality: Target wound has adequate granulation tissue and vascularization.
    • Cancer exclusion: Member does not have a history of squamous cell carcinoma in the affected wound(s) that will receive treatment.
    • Infection exclusion: Member does not have an active infection in the affected wound(s) that will receive treatment.
  7. Recent graft exclusion: Member has not received a skin graft in the past three months.
  8. Combination therapy exclusion: Vyjuvek will not be used in combination with Filsuvez (birch triterpenes) or Zevaskyn (prademagene zamikeracel) in the same wound.
  9. Infection exclusion: Member does not have an active infection in the affected wound(s) that will receive treatment.
  10. Target wound quality: Member's target wound has adequate granulation tissue and vascularization.
  11. Combination therapy exclusion: Vyjuvek will not be used in combination with Filsuvez (birch triterpenes) or Zevaskyn (prademagene zamikeracel) in the same wound.
  12. Vyjuvek Maximum Weekly Dose
    MedicationVyjuvek
    Maximum weekly dose4 × 10^9 PFU
    Maximum weekly volume2 mL